MCID: ALM001
MIFTS: 56

Al Amyloidosis

Categories: Rare diseases, Metabolic diseases, Nephrological diseases, Bone diseases, Genetic diseases, Neuronal diseases, Cardiovascular diseases, Blood diseases

Aliases & Classifications for Al Amyloidosis

MalaCards integrated aliases for Al Amyloidosis:

Name: Al Amyloidosis 50
Primary Systemic Amyloidosis 50 69
Primary Amyloidosis 50 69
Hereditary Amyloid Nephropathy Due to Lysozyme Variant 56
Familial Amyloid Nephropathy Due to Lysozyme Variant 56
Hereditary Renal Amyloidosis Due to Lysozyme Variant 56
Familial Renal Amyloidosis Due to Lysozyme Variant 56
Immunoglobulin Deposition Disease 69
Primary Systemic Al Amyloidosis 50
Amyloidosis Primary Systemic 50
Light Chain Amyloidosis 50
Primary Al Amyloidosis 50
Systemic Al Amyloidsis 50
Lysozyme Amyloidosis 56
Amyloidosis Primary 52
Alys Amyloidosis 56
Amyloidosis Al 50

Characteristics:

Orphanet epidemiological data:

56
alys amyloidosis
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide);

Classifications:



Summaries for Al Amyloidosis

NIH Rare Diseases : 50 al amyloidosisis the most common form of amyloidosis, a group of disorders in which an abnormal protein called amyloid builds up in tissues and organs. the signs and symptoms of al amyloidosis vary among patients because the build up may occur in the tongue, intestines, muscles, joints, nerves, skin, ligaments, heart, liver, spleen, or kidneys. to diagnose al amyloidosis, healthcare professionals use blood or urine tests to identify signs of amyloid protein and a biopsy to confirm the diagnosis. treatment may include chemotherapy directed at the abnormal plasma cells, stem cell transplantation, or other treatments based on which symptoms have developed. last updated: 7/17/2015

MalaCards based summary : Al Amyloidosis, also known as primary systemic amyloidosis, is related to amyloidosis, primary localized cutaneous, 1 and amyloidosis, primary localized cutaneous, 2, and has symptoms including renal insufficiency, proteinuria and nephrotic syndrome. An important gene associated with Al Amyloidosis is LYZ (Lysozyme), and among its related pathways/superpathways are Innate Immune System and Complement and coagulation cascades. The drugs Ketamine and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Al Amyloidosis

Diseases in the Amyloidosis family:

Amyloidosis, Hereditary, Transthyretin-Related Al Amyloidosis
Amyloidosis Aa Hereditary Amyloidosis
Primary Localized Amyloidosis Ah Amyloidosis

Diseases related to Al Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
id Related Disease Score Top Affiliating Genes
1 amyloidosis, primary localized cutaneous, 1 12.1
2 amyloidosis, primary localized cutaneous, 2 12.1
3 primary cutaneous amyloidosis 11.7
4 multiple myeloma 11.5
5 light chain deposition disease 11.0
6 primary localized amyloidosis 10.9
7 amyloidosis 10.9
8 amyloidosis, hereditary, transthyretin-related 10.7
9 hepatitis 10.0
10 renal adenoma 10.0 LYZ VWF
11 esophageal adenosquamous carcinoma 10.0 CLU LYZ
12 factor x deficiency 10.0
13 nephrotic syndrome 10.0
14 lymphoma 9.9
15 cardiomyopathy 9.9
16 central nervous system vasculitis 9.9 CLU LYZ
17 cholestasis 9.8
18 macroglossia 9.8
19 glomerulonephritis 9.8
20 leukemia 9.8
21 mediastinitis 9.8
22 neuropathy 9.8
23 macroglobulinemia 9.8
24 endotheliitis 9.8
25 rheumatoid arthritis 9.7
26 arthritis 9.7
27 b-cell lymphomas 9.7
28 dilated cardiomyopathy 9.7
29 colitis 9.7
30 atrial fibrillation 9.7
31 disseminated intravascular coagulation 9.7
32 polyneuropathy 9.7
33 hypothyroidism 9.7
34 intrahepatic cholestasis 9.7
35 hepatitis c 9.7
36 plasmacytoma 9.7
37 gastroduodenitis 9.7
38 acquired von willebrand syndrome 9.7
39 adult respiratory distress syndrome 9.6 TNNT2 VWF
40 factor v deficiency 9.5
41 hepatitis c virus 9.5
42 pick disease 9.5
43 temporal arteritis 9.5
44 deficiency anemia 9.5
45 pulmonary hypertension 9.5
46 acute liver failure 9.5
47 adult t-cell leukemia 9.5
48 congestive heart failure 9.5
49 diffuse large b-cell lymphoma 9.5
50 hematopoietic stem cell transplantation 9.5

Graphical network of the top 20 diseases related to Al Amyloidosis:



Diseases related to Al Amyloidosis

Symptoms & Phenotypes for Al Amyloidosis

Human phenotypes related to Al Amyloidosis:

32 (show top 50) (show all 54)
id Description HPO Frequency HPO Source Accession
1 renal insufficiency 32 frequent (33%) HP:0000083
2 proteinuria 32 frequent (33%) HP:0000093
3 nephrotic syndrome 32 frequent (33%) HP:0000100
4 enlarged kidney 32 frequent (33%) HP:0000105
5 nephropathy 32 frequent (33%) HP:0000112
6 macroglossia 32 occasional (7.5%) HP:0000158
7 xerostomia 32 occasional (7.5%) HP:0000217
8 hematuria 32 occasional (7.5%) HP:0000790
9 hypertension 32 occasional (7.5%) HP:0000822
10 adrenal insufficiency 32 occasional (7.5%) HP:0000846
11 goiter 32 occasional (7.5%) HP:0000853
12 purpura 32 occasional (7.5%) HP:0000979
13 keratoconjunctivitis sicca 32 occasional (7.5%) HP:0001097
14 polyneuropathy 32 occasional (7.5%) HP:0001271
15 congestive heart failure 32 frequent (33%) HP:0001635
16 hypertrophic cardiomyopathy 32 hallmark (90%) HP:0001639
17 bradycardia 32 occasional (7.5%) HP:0001662
18 asplenia 32 occasional (7.5%) HP:0001746
19 malabsorption 32 occasional (7.5%) HP:0002024
20 dyspnea 32 frequent (33%) HP:0002094
21 pleural effusion 32 occasional (7.5%) HP:0002202
22 gastrointestinal hemorrhage 32 occasional (7.5%) HP:0002239
23 hepatomegaly 32 frequent (33%) HP:0002240
24 autonomic dysregulation 32 occasional (7.5%) HP:0002271
25 aortic root dilatation 32 occasional (7.5%) HP:0002616
26 lymphadenopathy 32 frequent (33%) HP:0002716
27 osteoarthritis 32 occasional (7.5%) HP:0002758
28 upper airway obstruction 32 occasional (7.5%) HP:0002781
29 arthralgia 32 frequent (33%) HP:0002829
30 abnormality of chromosome segregation 32 frequent (33%) HP:0002916
31 arthropathy 32 frequent (33%) HP:0003040
32 abnormal ekg 32 frequent (33%) HP:0003115
33 elevated alkaline phosphatase 32 frequent (33%) HP:0003155
34 decreased antibody level in blood 32 occasional (7.5%) HP:0004313
35 intermittent claudication 32 occasional (7.5%) HP:0004417
36 orthostatic hypotension due to autonomic dysfunction 32 occasional (7.5%) HP:0004926
37 autonomic bladder dysfunction 32 occasional (7.5%) HP:0005341
38 monoclonal immunoglobulin m proteinemia 32 frequent (33%) HP:0005508
39 abnormality of bone marrow cell morphology 32 occasional (7.5%) HP:0005561
40 interstitial pulmonary abnormality 32 frequent (33%) HP:0006530
41 multiple myeloma 32 frequent (33%) HP:0006775
42 abnormal blistering of the skin 32 occasional (7.5%) HP:0008066
43 abnormality of the submandibular glands 32 occasional (7.5%) HP:0010287
44 mechanical ileus 32 occasional (7.5%) HP:0010676
45 edema of the lower limbs 32 frequent (33%) HP:0010741
46 plasmacytoma 32 occasional (7.5%) HP:0011857
47 acute infectious pneumonia 32 frequent (33%) HP:0011949
48 hepatitis 32 occasional (7.5%) HP:0012115
49 fatigue 32 hallmark (90%) HP:0012378
50 chronic constipation 32 frequent (33%) HP:0012450

MGI Mouse Phenotypes related to Al Amyloidosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.72 CLU LGALS3 LYZ TNNT2 VWF
2 homeostasis/metabolism MP:0005376 9.63 CLU CTSK LGALS3 LYZ TNNT2 VWF
3 digestive/alimentary MP:0005381 9.56 VWF CTSK LGALS3 LYZ
4 immune system MP:0005387 9.35 CLU CTSK LGALS3 LYZ VWF
5 nervous system MP:0003631 9.02 CLU CTSK LGALS3 LYZ VWF

Drugs & Therapeutics for Al Amyloidosis

Drugs for Al Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 255)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
4
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
7
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
8
Mechlorethamine Approved Phase 3,Phase 1,Phase 2 51-75-2 4033
9
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
10
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
13
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Dalteparin Approved Phase 3 9005-49-6
17
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
18
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
19
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
20
Morphine Approved, Investigational Phase 3 57-27-2 5288826
21
Daratumumab Approved Phase 3,Phase 1,Phase 2 945721-28-8
22 Ixazomib Approved Phase 3,Phase 1,Phase 2 1072833-77-2
23
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
24
Glycine Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 56-40-6 750
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Analgesics Phase 3,Phase 2
27 Anesthetics Phase 3
28 Anesthetics, Dissociative Phase 3
29 Anesthetics, General Phase 3
30 Anesthetics, Intravenous Phase 3
31 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
32 Excitatory Amino Acid Antagonists Phase 3
33 Excitatory Amino Acids Phase 3
34 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
35 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
36 Alkylating Agents Phase 3,Phase 2,Phase 1
37 Antiemetics Phase 3,Phase 2,Phase 1
38 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
40 Autonomic Agents Phase 3,Phase 2,Phase 1
41 BB 1101 Phase 3,Phase 2,Phase 1
42 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
43 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
44 glucocorticoids Phase 3,Phase 2,Phase 1
45 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
46 Hormone Antagonists Phase 3,Phase 2,Phase 1
47 Hormones Phase 3,Phase 2,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
50
protease inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 162)

id Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis Completed NCT01998503 Phase 3 Bortezomib;dexamethasone;Melphalan
3 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis Completed NCT00344526 Phase 3 Melphalan;Dexamethasone
4 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3 dexamethasone;melphalan
5 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
6 A Trial for Systemic Light-chain (AL) Amyloidosis Completed NCT01277016 Phase 3 BMDex
7 Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
16 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
17 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
18 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
19 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
20 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Recruiting NCT03201965 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone, 40 mg;Daratumumab
21 Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis Recruiting NCT01659658 Phase 3 IXAZOMIB;Dexamethasone;Melphalan;Cyclophosphamide;Thalidomide;Lenalidomide
22 The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis Active, not recruiting NCT02312206 Phase 3 NEOD001
23 Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib Terminated NCT02489500 Phase 3 Bortezomib;Melphalan;Neupogen
24 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Unknown status NCT00064337 Phase 2 cyclophosphamide;dexamethasone;melphalan;thalidomide
25 Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) Unknown status NCT00981708 Phase 1, Phase 2 Lenalidomide, Dexamethasone and Cyclophosphamide
26 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
27 Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction Completed NCT00547365 Phase 1, Phase 2
28 A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis Completed NCT00883623 Phase 2 Lenalidomide
29 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis Completed NCT00002849 Phase 2 dexamethasone
30 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00091260 Phase 2 dexamethasone;lenalidomide
31 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00679367 Phase 2 dexamethasone;lenalidomide;melphalan
32 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00790647 Phase 2 bortezomib;melphalan
33 Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis Completed NCT00166413 Phase 2 CC-5013
34 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Completed NCT01072773 Phase 2 bortezomib;cyclophosphamide;dexamethasone
35 Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis Completed NCT00607581 Phase 2 cyclophosphamide;lenalidomide;dexamethasone
36 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis Completed NCT00003853 Phase 2 4'-iodo-4'-deoxydoxorubicin
37 Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis Completed NCT00089167 Phase 2 dexamethasone;melphalan;thalidomide
38 Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed NCT00564889 Phase 2 cyclophosphamide;dexamethasone;lenalidomide
39 High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis Completed NCT00003353 Phase 2 melphalan
40 Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Completed NCT01194791 Phase 2 Lenalidomide;Cyclophosphamide;Dexamethasone
41 Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Completed NCT01707264 Phase 1, Phase 2 NEOD001
42 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis Completed NCT00007995 Phase 2 busulfan;cyclophosphamide;melphalan
43 A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) Completed NCT02015312 Phase 2 Epigallocatechin-3-gallate (EGCG);Placebo
44 Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Completed NCT01527032 Phase 2 melphalan, thalidomide and dexamethasone
45 Autologous Stem Cell Rescue for Primary Amyloidosis Completed NCT00186407 Phase 2
46 Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis Completed NCT00017680 Phase 2 Melphalan
47 High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis Completed NCT00002810 Phase 2 melphalan
48 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis Completed NCT00458822 Phase 2 bortezomib;dexamethasone
49 Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden Completed NCT00651937 Phase 2 Melphalan;Granulocyte-colony stimulating factor (G-CSF)
50 Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis Completed NCT00298766 Phase 1, Phase 2 VELCADE

Search NIH Clinical Center for Al Amyloidosis

Genetic Tests for Al Amyloidosis

Anatomical Context for Al Amyloidosis

MalaCards organs/tissues related to Al Amyloidosis:

39
Bone, Bone Marrow, Liver, Kidney, Heart, Skin, Testes

Publications for Al Amyloidosis

Articles related to Al Amyloidosis:

(show top 50) (show all 559)
id Title Authors Year
1
Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. ( 28926601 )
2017
2
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. ( 27729322 )
2017
3
Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. ( 28758811 )
2017
4
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. ( 28807981 )
2017
5
The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. ( 28737773 )
2017
6
Attitudes about when and how to treat patients with AL amyloidosis: an international survey. ( 28857614 )
2017
7
Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected? ( 28737209 )
2017
8
Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. ( 28648672 )
2017
9
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. ( 28850697 )
2017
10
News in AL Amyloidosis ASH 2016: AA rapidly evolving field of investigation. ( 28725274 )
2017
11
Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma. ( 28701686 )
2017
12
Unravelling hypothyroidism in AL amyloidosis: Authors' reply. ( 28861923 )
2017
13
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. ( 28832959 )
2017
14
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. ( 28698204 )
2017
15
Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review. ( 28056871 )
2017
16
Pathology and diagnosis of renal non-AL amyloidosis. ( 28828707 )
2017
17
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. ( 28699650 )
2017
18
Light Chain (AL) Amyloidosis: The Journey to Diagnosis. ( 28808991 )
2017
19
Acquired von Willebrand Syndrome Associated to Secondary IgM MGUS Emerging after Autologous Stem Cell Transplantation for AL Amyloidosis. ( 28512563 )
2017
20
Analysis of deposited peptides in amyloid lesions of AL amyloidosis by mass spectrometry. ( 28679987 )
2017
21
Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. ( 28754546 )
2017
22
AL amyloidosis, hypothyroidism and reduced tissue availability of thyroid hormones by thyroid hormone-binding immunoglobulin: a new possible perspective. ( 28805259 )
2017
23
Successful Treatment of Hepatitis C Infection While Receiving Concurrent Chemotherapy for AL Amyloidosis. ( 26869507 )
2016
24
Monoclonal IgM-related AL amyloidosis. ( 27825470 )
2016
25
Primary AL amyloidosis presenting with systemic lymphadenopathy with calcification. ( 27631125 )
2016
26
Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. ( 26812792 )
2016
27
Defining ultrahigh-risk AL amyloidosis with VWF. ( 27445410 )
2016
28
Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients (.) ( 27460276 )
2016
29
Primary AL amyloidosis presenting as lower motor neuron disease. ( 27084240 )
2016
30
Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. ( 27288311 )
2016
31
Penile ulcers complicating systemic AL amyloidosis: a case report. ( 27187183 )
2016
32
Bendamustine-Induced Nephrogenic Diabetes Insipidus inA aA Patient With AL Amyloidosis. ( 27780577 )
2016
33
Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis. ( 26760309 )
2016
34
Ascites in the course of plasma cell myeloma complicated by AL-amyloidosis. ( 27531413 )
2016
35
Fatal recurrent dermatoneuro syndrome associated with systemic AL amyloidosis. ( 26754417 )
2016
36
Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis. ( 26961452 )
2016
37
Rare and unusual clinicopathologic presentation of renal AL amyloidosis. ( 27186381 )
2016
38
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. ( 27416985 )
2016
39
Mediastinal nodular AL-amyloidosis with progressive calcification. ( 27521579 )
2016
40
Editor's choice: Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease? ( 26908764 )
2016
41
Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study. ( 27832515 )
2016
42
Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. ( 27183092 )
2016
43
Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis. ( 27682970 )
2016
44
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. ( 27904139 )
2016
45
Bone marrow amyloid spherulites in a case of AL amyloidosis. ( 27067483 )
2016
46
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. ( 27211265 )
2016
47
Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. ( 26773409 )
2016
48
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. ( 27257181 )
2016
49
New and developing therapies for AL amyloidosis. ( 28002971 )
2016
50
Aggregation of Full Length Immunoglobulin Light Chains from AL Amyloidosis Patients Is Remodeled by Epigallocatechin-3-gallate. ( 28031465 )
2016

Variations for Al Amyloidosis

Expression for Al Amyloidosis

Search GEO for disease gene expression data for Al Amyloidosis.

Pathways for Al Amyloidosis

Pathways related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 CLU CTSK LGALS3 LYZ VWF
2 10.77 CLU VWF

GO Terms for Al Amyloidosis

Cellular components related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CLU CTSK LGALS3 LYZ
2 extracellular region GO:0005576 9.35 CLU CTSK LGALS3 LYZ VWF
3 platelet alpha granule lumen GO:0031093 9.16 CLU VWF
4 extracellular matrix GO:0031012 8.8 CLU LGALS3 VWF

Biological processes related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 8.96 CLU VWF
2 antimicrobial humoral response GO:0019730 8.62 CLU LYZ

Molecular functions related to Al Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 8.96 CLU VWF
2 collagen binding GO:0005518 8.62 CTSK VWF

Sources for Al Amyloidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....